Resources
AI in pharma is an architecture decision.
Most companies are arguing about model selection. The ones that win are quietly building the unglamorous foundations underneath.
AI in pharma is an architecture decision rather than a procurement one. Frontier models turn over every few months, so the durable investment is the layer underneath: semantic grounding, data contracts, permissions, and MLR workflows that survive regulatory audit. This collection covers how pharma organizations should structure AI so deployments outlive the model they launched on.
That architecture is not exciting. It is ontology layers, governance scaffolding, MLR workflow design, audit trails, and human in the loop accountability. Boring infrastructure that does not photograph well in an annual report. Foundational work that makes the difference between an AI deployment that ships and one that quietly stalls in pilot for the third year running.
This collection covers how to think about AI in pharma. What to fund. What to skip. Why the deployment model matters more than the model selection. Why human approval is not a feature in pharma AI, it is the only model that survives a regulatory audit. If you are a pharma operator trying to make AI decisions that compound, the writing here is meant for you.
Key Insights
What the writing is showing.
Pharma does not have an AI problem. It has a building problem.
McKinsey estimates 75 to 85 percent of pharma workflows can be enhanced or automated by AI agents.
Merck committed roughly 1 billion dollars to agentic AI with Google Cloud, but the architecture it bought is reproducible at a fraction of the spend.
Read Deeper
Articles in this collection.
AI, Business
AI Agent vs AI Copilot vs AI Twin vs AI Assistant: The Complete 2026 Guide
AI agents, copilots, twins, and assistants are not the same product. Here is what actually separates them, what each costs, and how to pick the right one in 2026.
Sep 13 · 3 min read
AI, Pharma
Your AI Pilot Worked. So Why Is It Still A Pilot 18 Months Later?
Pharma AI pilots work. The vendors deliver. The pilots prove the model. Then they sit there for 18 months. Here are 6 reasons most never scale, and what changes that.
Jun 23 · 3 min read
Pharma, AI
Merck Just Spent $1 Billion on Agentic AI. Here Is What They Actually Bought.
Merck just signed a $1B deal with Google for agentic AI. Here is what they actually bought, and how a mid-tier pharma gets 80% of the value for 1% of the spend.
Jun 21 · 3 min read
AI
Your Pharma Has Six AI Vendors. Here Is How to Get to One.
Your mid-size pharma runs six AI vendors. Six contracts, six governance regimes, six audit trails. Here is the 16-week consolidation pattern to one unified agent layer.
Jun 15 · 3 min read
AI
The AI Agent Architecture Every Pharma Will Eventually Build. Here Is the Blueprint.
Every pharma over 500 people will eventually build an AI agent layer. The architecture is converging on the same six components. Here is the blueprint and how I deploy it.
Jun 11 · 3 min read
AI
3 Reasons Your Pharma AI Pilot Is Stuck in PowerPoint (And the 90-Day Path Out)
Two-thirds of organizations are stuck in AI pilot mode. 95% of pharma AI pilots never deliver business value. Here are the three reasons yours is one of them, and the 90-day plan that gets you out.
Jun 10 · 3 min read
AI
Your Pharma Is Losing 21 Days on Every Cross-Functional Decision. Here Is How to Stop It.
Every cross-functional decision inside your pharma is routing through five to twelve stakeholders, and the math on that cascade adds twenty-one days to your timeline before anyone has actually disagreed
Jun 8 · 3 min read
Pharma, AI
Why Generative AI in Pharma Marketing Will Trigger the Next FDA Wave
In 2025, the FDA issued over two hundred enforcement letters challenging prescription drug advertising, the highest annual total in nearly twenty-five years
May 29 · 3 min read
Pharma, AI
Why Mid-Size Pharma Will Lose the AI Race
Eli Lilly is building a one-billion-dollar AI supercomputer with Nvidia. Johnson & Johnson, Roche, Pfizer, and Novo Nordisk have direct partnerships with the four largest AI infrastructure providers in the world.
May 28 · 3 min read
Pharma, AI
AI in Pharmacovigilance: The 18-Month Window
Pharmacovigilance is the function where the volume math has already broken. Manual processing cannot scale. AI is forced, not optional.
May 26 · 3 min read
AI, Pharma
Why Pharma's Best AI Bets Are Boring (And Why That's the Point)
The AI investments that will define pharma's next decade are not the flashy ones. They are the boring ones. Here is what to look for and why your CFO will not approve them.
May 10 · 3 min read
AI, Business, Pharma
How to Brief an AI Agent Like a Senior Partner: A Pharma Operator's Framework
Most pharma teams brief AI agents like search engines. The teams getting results brief them like senior associates. Here is the framework that changes the output.
May 6 · 3 min read
Pharma, AI
Why I Built Human in the Loop for Pharma
Pharma leaders make hundreds of decisions a week with no audit trail. Human in the Loop is the AI deployment model that makes pharma accountable.
Apr 29 · 3 min read
Pharma, AI
AI in Pharma Is an Architecture Decision, Not a Procurement One
Most pharma boardrooms ask which AI model to buy. The companies winning are asking which architecture to build. Here is why that matters.
Apr 8 · 3 min read
Questions
What people ask about ai in pharma.
Want to talk about how this applies to your organization?
30 minute call. No deck. We will figure out if I can help.